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The function of guanine-based purines (GBPs) is mostly attributed to the intracellular
modulation of heteromeric and monomeric G proteins. However, extracellular effects
of guanine derivatives have also been recognized. Thus, in the central nervous system
(CNS), a guanine-based purinergic system that exerts neuromodulator effects, has been
postulated. The thesis that GBPs are neuromodulators emerged from in vivo and in vitro
studies, in which neurotrophic and neuroprotective effects of these kinds of molecules
(i.e., guanosine) were demonstrated. GBPs induce several important biological effects
in rodent models and have been shown to reduce seizures and pain, stabilize mood
disorder behavior and protect against gliomas and diseases related with aging, such
as ischemia or Parkinson and Alzheimer diseases. In vitro studies to evaluate the
protective and trophic effects of guanosine, and of the nitrogenous base guanine,
have been fundamental for understanding the mechanisms of action of GBPs, as
well as the signaling pathways involved in their biological roles. Conversely, although
selective binding sites for guanosine have been identified in the rat brain, GBP receptors
have not been still described. In addition, GBP neuromodulation may depend on the
capacity of GBPs to interact with well-known membrane proteins in glutamatergic and
adenosinergic systems. Overall, in this review article, we present up-to-date GBP biology,
focusing mainly on the mechanisms of action that may lead to the neuromodulator role
of GBPs observed in neurological disorders.
Keywords: guanosine, neuromodulation, purinergic system, Parkinson’s disease, Alzheimer’s disease,
glutamatergic system
PURINES AS INTERCELLULAR MODULATORS
Purines are endogenous organic molecules that are essential for all cells. For instance,
they are structural constituents of nucleic acids, are part of coenzyme structures and act
as second messengers in intracellular signaling pathways. Purines consist of the two-ring
nitrogenous bases adenine and guanine, together with the derivatives of these: nucleosides
(nitrogenous bases plus a pentose sugar, usually ribose) and nucleotides (nitrogenous bases
plus ribose and phosphate) that are mono-, di- or tri-phosphorylated. Adenine derivatives
include the nucleoside adenosine, and the nucleotides adenosine-5′-monophosphate (AMP),
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FIGURE 1 | Purine metabolism. The guanine nucleotides guanosine-5′
-triphosphate (GTP), guanosine-5′-diphosphate (GDP) and
guanosine-5′-monophosphate (GMP) are sequentially dephosphorylated by
ecto-nucleotidases (i.e., Ecto-NTPDase and Ecto-5’-nucleotidase), thus
generating guanosine. Guanosine is hydrolyzed by PNP generating the purine
base guanine. By action of a guanine deaminase (GDA), guanine is converted
into xanthine and subsequently to uric acid by the action of a xanthine
oxidase. Adenine nucleotides are also hydrolyzed forming the nucleosides
adenosine and inosine. The following nitrogenous bases, hypoxanthine,
xanthine and uric acid, are formed intracellularly. Ecto-NTPDase,
ecto-nucleotide diphosphohydrolase or apyrase; ADA, adenosine deaminase;
AdoK, adenosine kinase; APRT, adenine phosphoribosyl transferase; HGPRT,
hypoxanthine-guanine phosphoribosyl transferase; PNP, purine nucleoside
phosphorylase. APRT and HGPRT are mainly involved in the intracellular
salvage purines pathway.
adenosine-5′-diphosphate (ADP) and adenosine-5′-
triphosphate (ATP). Guanine derivatives include the nucleoside
guanosine, and the nucleotides guanosine-5′-monophosphate
(GMP), guanosine-5′-diphosphate (GDP) and guanosine-
5′-triphosphate (GTP). Purines also include some related
metabolites, such as the nucleoside inosine and the nitrogenous
base hypoxanthine, from the catabolism pathway of adenosine;
and the bases xanthine and uric acid, from the catabolism
of guanine and hypoxanthine (Figure 1). When released
into the extracellular space, nucleotides are hydrolyzed by
ecto-nucleotidases located at the cellular membrane surface
(Zimmermann and Braun, 1996). The main ecto-nucleotide
triphosphatase (ecto-NTPase) are: ecto-ATPase, which
hydrolyzes ATP to ADP and GTP to GDP; ecto-ATP-
diphosphohydrolase or apyrase (ecto-NTPDase), which leads to
AMP from either ATP or ADP, and forms GMP from GTP or
GDP (Schadeck et al., 1989). Next, the nucleosides adenosine
and guanosine are the result of AMP or GMP hydrolization
by ecto-5′-nucleotidase (Zimmermann, 1996). Furthermore,
ecto-purine nucleoside phosphorylase (ecto-PNP) produces
guanine from guanosine (Giuliani et al., 2016), while guanine
deaminase (GDA) or cypin mediates guanine deamination to
xanthine (Miyamoto et al., 1982; Figure 1).
The concept of purines as intercellular modulators emerged
from the identification of extracellular effects of adenine-
based purines (ABPs) in different cell types. Drury and
Szent-Györgyi (1929) demonstrated that, after heart ischemia,
adenosine is released into the extracellular space, where it
promotes a negative chronotropic effect and also produces
coronary vessels vasodilatation. Later, ATP was recognized to
have both extracellular and intracellular effects, i.e., in the
maintenance of energetic cellular metabolism (Lipmann, 1941).
In the 1970s, Geoffrey Burnstock introduced the concept of
purinergic nerves and purinergic neurotransmission (Burnstock
et al., 1970; Burnstock, 1972). Since then, adenosine and ATP
have been considered to be important neuromodulators in
the central nervous system (CNS; Cunha, 2005; Jacobson and
Gao, 2006; Burnstock et al., 2011; Tozaki-Saitoh et al., 2011;
Ciruela et al., 2012). Meanwhile, opposed to the multiple actions
reported for ABP, the importance of guanine-based purines
(GBPs) has mostly been ascribed to their role as regulators
of G protein function. G proteins (formerly named guanine-
nucleotide regulatory proteins or GTP-binding proteins) are
key to signal transduction of the so-called G protein-coupled
receptors (GPCRs) to intracellular effectors (Rodbell et al., 1971).
Thus, G protein activity is, up to now, modulated by the
interactions with GDP or GTP in the basal and activated states,
respectively (Taylor, 1990). Similarly, low molecular monomeric
G protein activity is also modulated by interaction with GTP
and GDP (Hepler and Gilman, 1992); while other GBPs, such as
GMP, guanosine or guanine, have not been reported to interact
with G proteins.
In recent years, it has been shown that, apart from the
intracellular regulation of G proteins, GBPs have important
extracellular effects in different tissues, especially in the CNS.
Indeed, similarly to the vesicular storage reported for ATP
(Gualix et al., 1999), it was found that GTP was also stored in
synaptic vesicles, suggesting this guanine nucleotide would be a
neurotransmitter in the brain (Santos et al., 2006). Thus, together
with the existence of an adenosine-based purinergic system, a
guanine-based purinergic system has been proposed (Schmidt
et al., 2007). In the present review article, we report and discuss
how the guanine-based purinergic system is organized in the
nervous system and highlight the fundamental neuromodulator
and regulatory role of these molecules.
EXTRACELLULAR ROLES OF
GUANINE-BASED PURINES
GBPs function in the extracellular milieu was first observed when
assessing GBP levels after ischemic injury. Interestingly, it was
observed that GBP were rapidly released and that their levels
remain elevated until 7 days (Uemura et al., 1991). Similarly,
astrocytes subjected to hypoxic or hypoglycaemic situations
released different kinds of purine nucleotides, and extracellular
levels of GBPs were shown to reach levels three-fold higher than
those of ABPs (Ciccarelli et al., 1999). Also, it was possible to
detect extracellular GBPs in human cerebrospinal fluid (CSF),
both in physiological and pathological conditions (Regner et al.,
1997). These findings prompted the proposal that GBPs might
represent an endogenous restorative system that is activated
after injury. In this context, upon brain injury, hydrolysis of
the released nucleotides would occur, leading to the formation
of the respective nucleosides, which may possess a protective
effect.
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In the CNS, the first modulatory effects of extracellular
GBPs were demonstrated in the glutamatergic system (Schmidt
et al., 2007), the main excitatory neurotransmission system
in the brain (Meldrum, 2000; Segovia et al., 2001). Besides
its essential trophic effects in the CNS, glutamate is capable
of promoting a cascade of events leading to cellular death,
widely known as excitotoxicity. Therefore, molecules that
modulate glutamate excitotoxicity without interfering with the
physiological functions of glutamate may play a fundamental role
in neuroprotection. In line with this, initial studies evaluating
extracellular GBP functions, indicated that guanine nucleotides
would displace glutamate from its receptors (Schmidt et al., 2007;
Lanznaster et al., 2016). GBPs would also modulate glutamate-
induced cell responses in physiological (Tasca et al., 1995,
1998, 1999b; Regner et al., 1998; Tasca and Souza, 2000) and
pathological (Regner et al., 1998; Burgos et al., 2000b) situations.
Additionally, GBPs were shown to cause a delay in glutamate
uptake into synaptic vesicles (Tasca et al., 2004), suggesting
they modulate synaptic glutamate turnover. Moreover, other
studies showed that guanosine would also modulate glutamate
transporter activity (Dal-Cim et al., 2011, 2013; Lanznaster et al.,
2016). In short, the identification of the extracellular actions
of GBPs as intercellular messengers was possible due to five
pieces of evidences: (1) GBPs can be found in the extracellular
space, where they are released upon certain harmful conditions;
(2) hydrolization of extracellular guanine nucleotides leads to
the formation of guanosine and guanine; (3) GTP is stored in
synaptic vesicles; (4) glutamate binding is displaced by guanine
nucleotides; and (5) GBPs modulate glutamate transporter
activity. Based on these findings, it can be concluded that GBPs
act as endogenous modulators of glutamatergic transmission,
and it might result in the potentially critical role that these
molecules play in neuroprotection.
NEUROTROPHIC AND
NEUROPROTECTIVE EFFECTS OF GBPs
GBPs as Neurotrophic Agents
The trophic effects of GBPs, especially GTP and guanosine,
in the CNS (i.e., proliferation in astrocytes and neuritogenesis
in neurons) have been widely studied and are supported
by many data (Neary et al., 1996; Rathbone et al., 1999;
Ciccarelli et al., 2001). For example, it was first shown
that GTP or guanosine treatment of cultured astrocytes
promoted cell proliferation due to guanosine-induced adenosine
release (Ciccarelli et al., 2001). Similarly, GTP or guanosine
was also capable of stimulating the release of neurotrophic
factors (i.e., fibroblast growth factor-2, FGF-2; nerve growth
factor, NGF) from cultured astrocytes (Middlemiss et al.,
1995; Gysbers and Rathbone, 1996a). In pheochromocytoma
(PC12) cells, GTP or guanosine enhanced NGF-induced neurite
arborization outgrowth (Gysbers and Rathbone, 1992, 1996b).
Similarly, guanosine induced this kind of neurite arborization
in PC12 cells, and also in cerebellar neurons, upon hypoxic
conditions (Thauerer et al., 2010). Finally, guanosine and NGF
co-treatment of PC12 cells enhanced the activity of antioxidant
enzyme heme-oxygenase-1 (HO-1) and also produced an
increase of cyclic GMP (cGMP) intracellular levels (Bau et al.,
2005).
There are also robust findings that support the idea that
GBPs play a role in neuron–astrocyte interactions. Thus, the
trophic effects of GBPs were evaluated in neurons co-cultured
with astrocytes, where GMP or guanosine increased the amount
of cerebellar neurons and modulated the organization of
the extracellular matrix proteins laminin and fibronectin in
astrocytes (Decker et al., 2007). Additionally, in another work, it
was demonstrated that GMP or guanosine increased the number
of cultured cerebellar neurons (Tasca et al., 2010). Therefore,
besides having a direct positive effect on neuronal viability, GMP
or guanosine may also induce the release of soluble factors from
astrocytes that favor the survival of cultured neurons. Altogether,
it would be stated that GBP effects are importantly involved in
neuronal migration and cell proliferation.
It should be noted that, in adulthood, neurogenesis occurs
in two brain areas: the subventricular zone (SVZ) of the lateral
ventricles and the subgranular zone (SGZ) in the dentate
gyrus of the hippocampus (Gage et al., 1998; Gage, 2000).
Indeed, in cultures of neural stem cell from the SVZ, it
was recently shown that guanosine treatment increased cell
proliferation and expression of brain-derived neurotrophic
factor (BDNF; Su et al., 2013). Interestingly, another role
for guanosine was reported. Thus, in a Parkinson’s disease
(PD) mouse model, the systemic administration of guanosine
stimulated neuroprogenitor cell proliferation in the SVZ
(Su et al., 2009). Moreover, guanosine was also capable of
increasing the number of FGF-2-positive cells, which have
been shown to be critical regulators of neuroprogenitor/stem
cell proliferation, survival and differentiation (Zhao et al.,
2008).
Neuroprotective Effects of GBPs
GBPs-mediated neuroprotective effects have been demonstrated
using in vivo animal models of CNS disorders and in vitro
and ex vivo models of excitotoxicity or oxidative damage. Here,
we mainly focus on reviewing the effects of GBPs in animal
models of seizures, ischemia, PD and Alzheimer’s disease (AD).
Also, we review some of the related in vitro and ex vivo
models of degeneration designed to identify the mechanisms
of GBP-induced neuroprotection. The effects of GBPs on other
CNS diseases are also briefly discussed.
Seizures
In vivo evaluation of seizures in rats or mice can be
performed by using quinolinic acid, an agonist of the ionotropic
glutamate receptor N-methyl-D-aspartate (NMDA) subtype,
which causes overstimulation of glutamatergic activity (Heyes
et al., 1990; Nakano et al., 1993; Meldrum, 1994). Interestingly,
acute administration of GMP or guanosine reduced quinolinic
acid-induced seizures by about 60% (Schmidt et al., 2000; Soares
et al., 2004; Tavares et al., 2005, 2008; Torres et al., 2010). In one
of those studies, the anticonvulsant effect of GMP was blocked
with the 5’-nucleotidase inhibitor alpha-beta-methylene-
adenosine-5’-diphosphate (AOPCP), which impedes the
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conversion of GMP to guanosine (Soares et al., 2004). This result
suggested that guanosine is the biologically active anticonvulsant
molecule. In line with this, guanosine was demonstrated to be
protective both when administered intracerebroventricularly
(Schmidt et al., 2005) and orally (Lara et al., 2001; de Oliveira
et al., 2004); showing that its anticonvulsant effect occurs
regardless the route of administration. Similarly, chronic
(2 weeks) oral guanosine administration was shown to decrease
quinolinic acid- and α-dendrotoxin-induced seizures (Vinadé
et al., 2003, 2005). It was also shown that guanosine canmodulate
the changes induced in electroencephalographic (EEG) signals
by quinolinic acid intracerebroventricular infusion and prevent
behavioral seizures (Torres et al., 2010). Finally, in WAG/Rij
rats, which is a genetic model of absence epilepsy, it was observed
that guanosine decreased spike-wave discharges related. This
effect was not dependent on adenosine receptor activation,
since guanosine-mediated effects were not altered by using
the non-selective adenosine receptor antagonist theophylline
(Kovács et al., 2015).
Taken together, the data from all these studies indicate
that GBPs (mainly guanosine) may modulate exacerbation of
glutamatergic transmission by decreasing epileptic activity and
seizures.
Ischemia
The most common cause of disability worldwide is brain
ischemia. In the brain, blood flow reduction leads to reduced
oxygen and glucose supplying, which leads to the failure
of cellular bioenergetics and ultimately to excitotoxicity
and oxidative stress (Durukan and Tatlisumak, 2007).
GBPs-mediated neuroprotective effects can be evaluated in
different brain ischemia models. One of them consists of
the unilateral occlusion of the carotid artery, which is then
exposed to a hypoxic atmosphere. This model is known as
a perinatal hypoxia-ischemia (HI). Interestingly, guanosine
was able to restore HI-induced reduction in glutamate
uptake (Moretto et al., 2005, 2009). Similarly, in a model of
neurological damage, such as the unilateral middle cerebral
artery occlusion (MCAO), it was observed that guanosine
displayed a neuroprotective effect, since it reduced the infarcted
area and it also improved gait disturbances or spontaneous
activity (Chang et al., 2008; Rathbone et al., 2011; Connell et al.,
2013). Additionally, the neuroprotective effects of guanosine
were evaluated in a rodent model of cerebral hypoperfusion
(reduced blood flow) due to permanent bilateral occlusion
of common carotid arteries. Interestingly, it was observed
that guanosine administration (orally, for 2 weeks) reversed
pyramidal neurons loss and glial fibrillary acidic protein (GFAP)
expression in the hippocampus. However, guanosine did not
prevent the cognitive deficit induced in this model of cerebral
hypoperfusion (Ganzella et al., 2012). Another ischemic model
in which the neuroprotective effects of guanosine have been
shown is that induced by thermocoagulation (Hansel et al.,
2014, 2015). Of note, when inducing permanent cortical focal
ischemia in rats, guanosine treatment reduced the percentage
of the infarcted area (around 40%). In addition, guanosine
reduced neuronal degeneration, prevented reactive oxygen
species (ROS) production and lipid peroxidation, which led
to an improvement in forelimb dysfunction. Guanosine also
reduced activation of microglia and restored the levels of
inflammatory mediators (i.e., tumor necrosis factor (TNF-α),
interleukins IL-1 or IL-6) in the infarcted area (Hansel et al.,
2015). Importantly, these neuroprotective effects occurred
when guanosine treatment was initiated just after the focal
ischemia.
Apart from the data obtained from animal models, in vitro
and ex vivo protocols can be useful tools to demonstrate
the neuroprotective effects of GBPs in ischemic situations.
For instance, brain slices subjected to oxygen and glucose
deprivation (OGD) is an ex vivo ischemia model that
allows the study of neuroprotective agents (Tasca et al.,
2015). In this way, guanosine-mediated neuroprotection was
observed in OGD-deprived hippocampal slices (Oleskovicz
et al., 2008). Interestingly, these effects were identified to
depend on the modulation of glutamate transporter activity
(Dal-Cim et al., 2016), since glutamate uptake was restored
to basal levels (Dal-Cim et al., 2011). Of note, guanosine
would also produce antioxidant effects, since it reduced
oxidative parameters (e.g., ROS production) and prevented the
depolarization of the mitochondrial membrane. Interestingly,
in the OGD model, guanosine has been shown to display
a number of important anti-inflammatory effects. Thus,
guanosine inhibited p65 (the active subunit of nuclear factor
kappa B (NF-κB) transcription factor) translocation to the
nucleus, or it also reduced inducible nitric oxide synthase
(iNOS) expression (Dal-Cim et al., 2013). Similarly, guanosine
diminished NO levels, similar to that obtained with neuronal
NOS (nNOS) or iNOS isoforms inhibition (Thomaz et al.,
2016).
Interestingly, glutamate challenge can also be used as
an ischemic-like protocol, since ischemic events increase
glutamate release and excitotoxicity. In hippocampal slices, upon
glutamate-mediated damage, guanosine decreased glutamate
release and prevented iNOS induction (Molz et al., 2011).
Guanosine was also capable of attenuating glutamate-induced
ROS production (Dalla Corte et al., 2012).
Altogether, these studies support a role for GBPs against
ischemia, which may act as neuroprotective agents. Thus,
GBPs would have the capacity of increasing the clearance of
extracellular glutamate, prevent inflammatory events, activate
antioxidant defenses and maintain mitochondria bioenergetics.
Parkinson’s Disease
PD is a neurodegenerative disorder, which is characterized by
the selective death of dopaminergic neurons at the substantia
nigra pars compacta (SNc). This loss causes important motor
symptoms (i.e., bradykinesia, rigidity or postural complications;
Olanow and Tatton, 1999). Several studies have evaluated the
effects of GBPs in in vivo models of PD and the mechanisms of
action of GBPs in ex vivo and in vitromodels of PD.
Interestingly, guanosine was shown to decrease neuronal
cell death and even produce an increase in SNc dopaminergic
terminals, which ultimately led to reduce bradykinesia in
a model of PD (i.e., proteasome inhibitor administration;
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Su et al., 2009). Another example of such neuroprotective
role for guanosine was found in the PD-related alpha-
synuclein A53T transgenic mouse model. Thus, this
mutation led to higher guanosine brain levels when mice
grew (the guanosine content would increase with aging),
thus eliciting a putative protective effect (Chen et al.,
2015).
Recently, the effectiveness of guanosine against dyskinesia
in three rodent models of movement impairment was reported
for the first time. Thus, guanosine ameliorated tremolous
jaw movements (TJM) and catalepsy of reserpinized mice. In
addition, guanosine potentiated contralateral rotations induced
by L-DOPA in unilaterally 6-hydroxydopamine (6-OHDA)-
injured rats and displayed antidyskinetic efficacy in the L-DOPA-
induced dyskinesia (LID) animal model. These results support
the potential usefulness of guanosine in PD management,
including its capacity to reduce dyskinesia when used in
combination with L-DOPA (Massari et al., 2017).
Moving to in vitro PD models, one of the most used
is the 1-methyl-4-phenyl pyridinium (MPP+) model. This
active metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) inhibits complex I activity in
mitochondria (Vila and Przedborski, 2003). Notably, guanosine
was able to prevent MPP+-induced apoptosis in SH-SY5Y
neuroblastoma cells (Pettifer et al., 2007). Conversely this effect
was not observed in C6 astroglial cells exposed to 6-OHDA,
which is another PD model (Giuliani et al., 2016).
Alzheimer’s Disease (AD)
AD is a neurodegenerative condition that affects approximately
36 million people worldwide (Mazurek, 2000; Karran et al.,
2011; Masters and Selkoe, 2012). Along with neuronal death,
amyloid-β (Aβ) plaques and neurofibrillary tangles are the main
neuropathological hallmarks of the brain of AD patients.
Different models have been used to study the neuroprotective
effects of GBPs in AD. For instance, in an in vivo model
of the pathology (intracerebroventricular infusion of Aβ1–40),
chronic guanosine treatment prevented the cognitive deficit
and anhedonic-like behavior induced in mice. Interestingly,
it was shown that Aβ1–40 altered glutamate transport, mainly
by increasing Na+-independent glutamate uptake, and that
guanosine treatment led to recovery from this glutamatergic
transmission imbalance (Lanznaster et al., 2017).
A few studies have evaluated the neuroprotective effects
of GBPs in in vitro models of AD (i.e., using Aβ peptides).
Thus, in Aβ-treated SH-SY5Y neuroblastoma cells, guanosine
was able to prevent apoptosis and ROS production (Pettifer
et al., 2004; Tarozzi et al., 2010). In addition, guanosine
also prevented β-secretase over activity and reduced Aβ1–42
levels upon oxidative stress (Tarozzi et al., 2010). Similarly, in
hippocampal astrocytes, guanosine prevented lipopolysaccharide
(LPS)-induced inflammatory and oxidative damage as well as
decreasing TNF- α and NF-κB levels by induction of HO-1
(Bellaver et al., 2015). Taken together, these data suggest that
guanosine attenuates the neuroinflammation and oxidative stress
induced by Aβ peptides.
Hepatic Encephalopathy (HE)
HE is a neurological disease that leads to cognitive impairment,
which is initiated by liver dysfunction and continues with
ammonia accumulation that causes alterations in extracellular
glutamate levels (Butterworth et al., 1987; Albrecht and Jones,
1999). To our knowledge, only a single study has evaluated the
effects of GBPs in HE. Thus, in rats subjected to bile duct ligation
(BDL), guanosine was able to reverse cognitive impairment,
although no changes were observed in ammonia levels. Of note,
in this model oxidative stress and increased CSF glutamate levels
were observed in the striatum and hippocampus, indicating that
guanosine could act at this level (Paniz et al., 2014).
Sepsis
Sepsis, which is a potentially fatal syndrome of physiological,
pathological and biochemical abnormalities associated with
infection, is another condition in which GBPs may be
effective. One of the existent models consists of caecal ligation
and perforation. This intervention leads to oxidative stress
in a number of brain regions (i.e., hippocampus, striatum,
cerebellum and cerebral cortex). Interestingly, guanosine (acute
administration) was shown to reduce lipid peroxidation,
suggesting it would be one of the mechanisms explaining
guanosine-mediated neuroprotective effects. In addition, chronic
(10 days) could reduce cognitive impairment and depressive-like
behavior (Petronilho et al., 2012).
Spinal Cord Injury
The neuroprotective effects of GBPs against spinal cord injury
have also been demonstrated. In a model in which the spinal
cord from rats was moderately damaged, thus leading to
chronic traumatic spinal cord injury, guanosine was able to
induce locomotor activity recovery (Jiang et al., 2003). Notably,
guanosine treatment also led to spinal cord higher levels
of bromo-deoxy-uridine (BrdU), which is a marker of cell
proliferation. Thus, new mature oligodendrocytes were observed
at the damaged area, which would allow remyelination and the
recovery of motor activity (Jiang et al., 2003, 2008). Indeed,
it is well-accepted that remyelination of the damaged area in
the spinal cord is critical for functional recovery (Gilson and
Blakemore, 1993; Horner et al., 2000).
Gliomas
Gliomas are considered the most aggressive type of brain
tumors. Therapies involve surgical resection, radiotherapy or
chemotherapy. One of the chemotherapeutic compounds most
commonly used is temozolomide (TMZ), which is an alkylating
drug that inhibits DNA replication and that has been shown to
have some efficacy in early diagnosed gliomas. A few studies
have analyzed the effects of GBPs on tumoral cells. Thus,
guanosine was evaluated as a therapeutic strategy in several
types of tumors, including lung cancer cells (Su et al., 2010),
melanoma cells (Naliwaiko et al., 2008), hepatoma cells (Yang
et al., 2005), leukemia and mastocytoma models (Iigo et al.,
1987) and an in vivo Ehrlich carcinoma model (Kim et al.,
1997).
In CNS tumors, the effect of guanosine was evaluated in the
A172 glioma cell line. Interestingly, guanosine was cytotoxic to
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glioma in concentrations that were not toxic to native brain
tissue (Molz et al., 2009), and to astrocytes in culture (Oliveira
et al., 2017). By evaluating the combination of guanosine with
the alkylating agent TMZ, it was shown that their cytotoxicity
arises from the potentiation of the apoptotic process and the
reduction of glioma cells migration. Guanosine also decreased
mitochondrial membrane potential, intracellular ATP levels, and
prevented the increase in glutamate release evoked by TMZ in
glioma cells (Oliveira et al., 2017). Despite all the evidences of
GBPs-mediated modulation of glutamatergic transmission, no
effects of guanosine on glutamate uptake release or on the activity
of glutamine synthetase have been observed (Yin et al., 2013).
Additionally, the cytotoxic effect of guanosine in gliomas was not
affected by glutamate receptors or transporters pharmacological
blockage; while, on the other hand, adenosine receptors would be
involved in guanosine-mediated cytotoxic effects (Oliveira et al.,
2017). To the best of our knowledge, the anti-tumorigenic effects
of guanosine in glioma cells still need further investigation.
Thus, it was clearly shown that guanosine activates survival
signaling pathways, which are able to induce neuroprotection
or trophic effects in non-tumoral cells (Lanznaster et al., 2016).
Accordingly, the cytotoxic effects of guanosine would also be
related to the regulation of cell growing and survival in tumoral
cells. These interesting results, together with themechanisms that
confer a dual-effect to guanosine (i.e., displaying a protective
action to healthy neural cells subjected to pathological conditions
and cytotoxic effect to SNC tumoral cells), need additional
evaluation to be unraveled.
Overall, the studies discussed here support important
neurotrophic and neuroprotective effects of GBPs, mainly
GTP, GMP and guanosine. We should note that most of the
neuroprotective effects observed in different pathological models
were obtained using guanosine, which may be probably due to
nucleotide hydrolysis occurring in the extracellular space.
GBP EFFECTS ON MODELS OF PAIN AND
MOOD DISORDERS
Anxiety, depression and pain are among the major causes
of disability worldwide. Glutamate transmission has been
described to be involved in the etiology and treatment of such
pathologies. For instance, ketamine, which is an antagonist for
NMDA glutamate receptors, was able to produce a fast-acting
antidepressant effect (Chaki and Fukumoto, 2015). Furthermore,
metabotropic glutamate receptor ligands have been shown to
possess analgesic properties (Kolber, 2015). Considering that
GBPs modulate glutamatergic transmission, it is reasonable
to infer that these molecules may also present anxiolytic,
antidepressant and analgesic effects.
The anxiolytic and antidepressant effects of GBPs have
been studied in some well-accepted models. For instance, rats
treated once with GMP or guanosine showed a decrease in
anxiogenic-like behavior, which were similar to that observed
with diazepam, a classic anxiolytic drug (Almeida et al.,
2010). Anxiolytic-like behavior induced by guanosine was also
observed after chronic treatment. Thus, guanosine (2 weeks
administration) increased anxiolytic-like behavior (Da Silva
and Elisabetsky, 2001; Vinadé et al., 2003). Also, a rapid
antidepressant effect, similar to that of ketamine, was observed
after a single oral administration of guanosine in mice (Bettio
et al., 2012). Guanosine also induced antidepressant-like effects
in mice subjected to acute restraint stress, a more translational
model associated with mood disorders that are secondary
effects of stressful lifetime events (for a review, see Yang
et al., 2015). Interestingly, the antidepressant-like effects of
guanosine could be due to its antioxidant activity, which would
reduce hippocampal oxidative damage induced by acute restraint
stress (Bettio et al., 2014). Finally, it was recently shown that
chronic guanosine treatment promoted an antidepressant-like
effect that might be associated with hippocampal neuroblasts
differentiation (Bettio et al., 2016b), suggesting a connection
between the antidepressant and neurogenic effects of guanosine
(Bettio et al., 2016a).
The possible analgesic effects of GBPs have also been
explored in different rodent models of pain. Guanosine reduced
nociception in several acute pain models, such as acetic acid,
formalin, glutamate or capsaicin injections. Guanosine treatment
inhibited nociception induced by intrathecal administration of
nociceptive substances, such as non-NMDA receptor agonists
(Schmidt et al., 2010). Similarly, guanine inhibited nociception
induced by glutamate and AMPA (de Oliveira et al., 2016).
Moreover, central administration of GMP, guanosine or guanine
in mice induced anti-nociception against thermal or chemical
(i.e., glutamate, capsaicin) stimuli (Schmidt et al., 2008; de
Oliveira et al., 2016), reinforcing the hypothesis of a CNS action
of GBPs.
MECHANISMS OF ACTION OF THE
PROTECTIVE AND TROPHIC EFFECTS OF
GBPs
As commented on above, the neuromodulatory effects of
GBPs have been studied in different models of ischemia
and neurodegenerative diseases, based on its action in
neuroinflammation, glutamatergic toxicity and mitochondrial
stress. These effects are mainly attributed to the capacity of GBPs
to modulate glutamatergic transport and inhibit both oxidative
stress and inflammatory damage. Meanwhile, the nucleoside
guanosine, which can activate several intracellular pathways of
secondmessengers that ultimately lead to a decrease in apoptosis,
would be the main element responsible for the protective and
trophic effects observed. Accordingly, most of the work aiming
to elucidate the mechanisms of action of GBPs has focused on
guanosine.
Several studies have demonstrated that GBP modulation
of glutamate transport has a major impact on the induction
of protection against excitotoxicity. Guanosine prevented
glutamate release in hippocampal slices subjected to
glutamatergic toxicity (Molz et al., 2011). Also, guanosine
stimulated glutamate uptake both in C6 astroglial cells deprived
from glucose (Quincozes-Santos et al., 2013) and in hippocampal
slices subjected to OGD (Dal-Cim et al., 2013). Interestingly,
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these effects were all mediated by phosphatidylinositol-3
protein kinase (PI3K) and protein kinase B (Akt) pathways
induction, followed by activation of mitogen-activated
protein kinase/extracellular-regulated kinase (MAPK/ERK).
In C6 cells, guanosine also activated protein kinase C
(PKC) and p38MAPK pathways to induce its protective
effect. Hence, based on these studies, we can conclude
that the effects of GBPs on glutamate transporters are
dependent on activation of these intracellular signaling
pathways. Supporting this view, a study showed that chronic
administration of GMP decreased the expression of NMDA
and AMPA receptor subunits and the glutamate transporters
EAAC1 and GLT-1 in the rat cerebral cortex (Ganzella et al.,
2012).
Regarding the ischemia and neurodegenerative models,
some intracellular pathways have been identified. Thus,
guanosine induced an increase in cell viability in hippocampal
slices subjected to OGD, which involved the activation of
several signaling pathways, including PKC, protein kinase
A (PKA), MAPK/ERK and PI3K (Oleskovicz et al., 2008).
PI3K activation is also involved in the anti-apoptotic effect of
guanosine in cultured human neuroblastoma cells challenged
with β-amyloid, which may include an increase in phospho-Akt
(Pettifer et al., 2004). Similarly, Akt expression and activation
was increased by guanosine, which protected astrocytes
challenged with the apoptotic drug staurosporine (Di Iorio
et al., 2004). Also, guanosine activated the PI3K/Akt/GSK3β
pathway, which inhibits the oxidative damage produced
by blocking mitochondrial complexes I and V (Dal-Cim
et al., 2012). Furthermore, in 6-OHDA-treated SH-SY5Y
cells, a model for PD, guanosine reduced p38MAPK and Jun
Kinase (JNK) activation, and increased phospho-Akt and
the expression of the anti-apoptotic protein, Bcl-2 (Giuliani
et al., 2012b). Finally, guanosine also activated the PI3K
pathway, which promotes anti-inflammatory effects. It also
inhibited iNOS induction via PI3K and MAPK/ERK activation
in hippocampal slices subjected to OGD (Dal-Cim et al.,
2013).
Notably, the involvement of the PI3K/Akt pathway in
GBP mechanisms of action has also been reported for the
antidepressant effects of guanosine. In addition, guanosine-
mediated antidepressant effects would also depend on the
activation of the mammalian target of rapamycin (mTOR; Bettio
et al., 2012).
Finally, regarding GBP-induced trophic effects, similar
signaling pathways have been reported. Guanosine promoted
neurite outgrowth in primary cerebellar neurons culture by
activation of PCK-related kinase-1 (PRK1; Thauerer et al., 2010),
which is a kinase involved in neuronal differentiation (Manser
et al., 2008). Similarly, by increasing cAMP accumulation,
phosphorylation of cAMP response element-binding protein
(CREB), and BDNF mRNA levels, guanosine induced neural
stem cell proliferation (Su et al., 2013). ERK, CaMKII, PKC, PI3K
and PKA were also involved in the trophic effect of guanosine
in cultured cerebellar neurons (Tasca et al., 2010). Indeed, the
effects of guanosine in the MAPK/ERK, CaMKII, PKC, PI3K
and PKA signaling pathways were observed to correlate with
the reorganization (from a diffuse to a fibrillary matrix) of
extracellular matrix proteins (Decker et al., 2007).
Overall, GBPs have been shown to activate several
intracellular pathways that promote biological effects (Figure 2).
It could then be concluded that the PI3K pathway is one of
the main intracellular routes involved in guanosine-induced
neuroprotection. Importantly, the identification of GBP
receptor(s), which is discussed below, will help to determine the
exact sequence of cell signaling pathways activated by GBPs.
GBP RECEPTORS: ARE GBPs ORPHAN
MOLECULES?
Selective binding sites for GBPs have already been confirmed
in rat brain membranes (Traversa et al., 2002, 2003); but GBP
receptors have not yet been identified. The existence of exclusive
protein receptors for GBPs are mainly supported by the use
of [3H]guanosine in rat brains. Accordingly, it was possible to
identify a single high-affinity guanosine binding site (dissociation
constant (Kd): 95.4± 11.9 nM; and apparent number of maximal
binding sites (Bmax): 0.57 ± 0.03 pmol/mg protein). Other
GBP and guanine metabolites were not potent displacers of
guanosine binding, strengthening the hypothesis that guanosine
is the ultimate GBP with biological effects. Nevertheless, recent
studies also highlighted biological effects for guanine, mainly
through modulating memory and learning impairment (Giuliani
et al., 2012a; Zuccarini et al., 2018).
One of the hypotheses to identify GBP (or guanosine)
receptors consists of their interaction with adenosine receptors.
However, given that adenosine, together with caffeine or
theophylline (non-selective adenosine receptor antagonists) were
not capable of displacing guanosine binding, it would seem
likely that other receptors may be involved. Indeed, in 2011, it
was identified a new putative GPCR that could be selectively
activated by guanosine (Volpini et al., 2011). On the other hand,
it would also seem likely that guanosine-mediated effects depend
on Gαi-protein activation. In this way, by means of the pertussis
toxin (PTX), an inhibitor of Gαi family proteins, it was possible
to reduce guanosine binding by 45% (Traversa et al., 2003).
Interestingly, other studies have focused on assessing whether
GBPs could also interact with transporters in the purinergic
system. Thus, it was found that a nucleoside transporter inhibitor
(nitrobenzylthioinosine) and an inhibitor of adenosine reuptake
(propentofylline) had no effect on guanosine binding (Traversa
et al., 2003).
Although the identification of putative GBP receptors is a
major goal, research has also focused on elucidating the role of
some well-characterized membrane proteins, such as glutamate
receptors and transporters, adenosine receptors and potassium
channels, which have been shown to be involved in the effects
of GBPs. The diverse findings suggest that GBPs, especially the
nucleoside guanosine, may act as multi-target neuromodulators
(Lanznaster et al., 2016).
Glutamate Transporters or Receptors
As discussed above, GBPs can modulate the activity of the
glutamatergic system; therefore, a possible direct interaction
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FIGURE 2 | Guanine-based purinergic signaling. This cartoon presents an overview of the main mechanisms involved in the neuroprotective effects of guanosine.
The release of guanine nucleotides (i.e., GTP) from synaptic vesicles or astrocytes produces extracellular guanosine (Guo) following hydrolysis by ecto-nucleotidases.
Guanine may also be formed by PNP activity on guanosine (not represented). A specific binding site for Guo has not been disclosed yet (i.e., guanosine receptor,
GuoR), but guanosine effects through calcium-dependent (big) conductance potassium (BK) channels, A1R and A2AR adenosine receptors, and glutamatergic
N-methyl-D-aspartate receptors (NMDARs) has been described. Guanosine promotes neuroprotection through an anti-inflammatory effect of inhibiting nuclear factor
kappa B (NF-κB) activation via MAPK/ERK. Additionally, guanosine presents antioxidant effects, as reducing the reactive oxygen species (ROS) generation,
preventing inducible nitric oxide synthase (iNOS) expression, and by increasing antioxidant defenses, as Heme-oxygenase-1 (HO-1) levels. Activation of PI3K/Akt,
protein kinase C (PKC) and MAPK/ERK by guanosine leads to stimulation of excitatory amino acid transporters (EAATs) activity. Guo also increases glutamine (Gln)
synthetase (GS) activity, thus reducing extracellular levels of glutamate (Glu) and protecting from glutamate excitotoxicity. Figure designed using image templates
from Servier Medical Art https://smart.servier.com/image-set-download/.
with glutamate receptors has been explored. Initial binding
studies showed that GBPs can displace the binding of glutamate
and its analogs to receptors in cell membrane preparations
(Sharif and Roberts, 1981; Butcher et al., 1986; Monahan et al.,
1988; Baron et al., 1989; Hood et al., 1990; Paas et al., 1996).
It was also shown that GBP-induced glutamate displacement
would not depend on the interaction with G proteins or on
the reduction of agonist binding to other GPCRs (Souza and
Ramírez, 1991; Paz et al., 1994; Ramos et al., 1997; Porciúncula
et al., 2002; Rotta et al., 2004). Reinforcing this hypothesis,
several studies showed that GMP is capable of decreasing
glutamate binding to receptors that do not interact with G
proteins (Burgos et al., 1998, 2000a,b; Aleu et al., 1999; Tasca
et al., 1999a; Tasca and Souza, 2000). Meanwhile, a number
of studies failed to observe a direct interaction of other GBPs
with glutamate receptors; guanosine and guanine had no effect
on the binding of glutamate and its analogs in total rat brain
membranes (Traversa et al., 2002; Vinadé et al., 2003). Binding
experiments with the post-synaptic density-enriched fraction
showed that GppNp (a poor hydrolyzable GTP analog) and
GMP displaced 40% and 36%, respectively, of glutamate binding,
while guanosine only displaced 23%. Similarly, AMPA binding
was not affected by guanosine, but was inhibited 21% and
25% by GppNp and GMP, respectively (Porciúncula et al.,
2002).
Considering the capacity of GBPs to modulate glutamate
transport, they could also interact with glutamate transporters.
Interestingly, the enhancement of glutamate uptake by guanosine
was first identified (Dal-Cim et al., 2011, 2013) together with the
fact that guanosine reduced glutamate release (Molz et al., 2011).
More recently, it was shown that synthetic glutamate transporter
inhibitors also inhibited the decrease in glutamate release
promoted by guanosine in an in vitro ischemia model (Dal-Cim
et al., 2016); suggesting a direct interaction of guanosine with
glutamate transporters. Nevertheless, despite these data, a direct
guanosine-glutamate transporter interaction has still not been
demonstrated.
Adenosine Receptors
To date, the involvement of the adenosinergic system in
guanosine-mediated effects is still a matter of debate. As
discussed above, binding studies seemed to rule out a direct
interaction of guanosine with adenosine receptors. However,
several biological effects induced by guanosine seem to be
dependent on adenosine receptors, namely on A1R and A2AR.
For example, although caffeine (a non-selective adenosine
receptor antagonist) did not alter guanosine binding in rat
brain (Traversa et al., 2003), it reversed the guanosine-
mediated anxiolytic-like behavior. In contrast, caffeine was not
able to block the effects of guanosine in capsaicin-induced
nociception (Schmidt et al., 2008), and the anticonvulsant effect
of guanosine on QA-induced seizures in mice (Lara et al.,
2001). Similarly, DPCPX, a selective A1R antagonist blocked
guanosine anti-nociceptive effects, but not SCH58361, an A2AR
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antagonist (Schmidt et al., 2008). Contradictorily, in cultured
cerebellar neurons, the trophic effects of guanosine depended
on A2AR, since the selective antagonist ZM241385 blocked
increased neuronal adhesionmediated by guanosine (Tasca et al.,
2010).
The involvement of A1R and A2AR in the guanosine
cytoprotective effects has been well characterized in in vitro
and ex vivo studies. In a human neuroblastoma cell line
(SH-SY5Y) subjected to mitochondrial oxidative stress, the
protective effects of guanosine were blocked by DPCPX and
ZM241385 (Dal-Cim et al., 2012). Guanosine induced a decrease
in ROS formation and mitochondrial membrane potential in
hippocampal slices subjected to OGD, which was dependent
on A1R, since DPCPX treatment inhibited the protective
effect of guanosine; however, A1R inhibition did not affect
the effect of guanosine on glutamate uptake. Also, PTX
blocked the effects of guanosine mediating recovery from
OGD-induced glutamate uptake impairment, suggesting an
interaction with a Gαi protein-coupled receptor. In contrast,
activation of A2AR by agonist CGS21680 inhibited guanosine-
induced neuroprotection, but A2AR blockade with the antagonist
ZM241385 did not; both assessed by cellular viability and
glutamate uptake (Dal-Cim et al., 2013). These controversial
results support the hypothesis that guanosine needs the presence
of both A1R and A2AR, which could be related to the fact that
these receptors directly interact forming the so-called receptor
oligomers. Indeed, it was demonstrated that these receptors
associate in the membrane of cells and interact with each other
in an antagonistic manner (Ciruela et al., 2006a,b; Ciruela,
2013). Further studies should be performed to demonstrate this
hypothesis.
Potassium Channels
Apart from its effects on GPCRs commented on above,
guanosine has also been shown to modulate the activity and
expression of K+ channels. In this way, the function of
inward rectifier K+ channels was increased upon guanosine
challenge in cultured rat cortical astrocytes (Benfenati et al.,
2006). Also, the neuroprotective effects of guanosine would
also depend on K+ channel activity. In line with this,
charybdotoxin, which blocks large-conductance Ca2+-activated
K+ channels (BK), was able to impede guanosine-mediated
cellular viability increase in OGD-treated hippocampal slices and
also blocked the protective effects of guanosine on SH-SY5Y
cells subjected to mitochondrial damage (Dal-Cim et al.,
2011, 2012). BK blockage also inhibited guanosine-mediated
recovery of the decreased glutamate uptake in hippocampal
slices subjected to OGD (Dal-Cim et al., 2011). It should
be noted that other potassium channels do not seem to
modulate guanosine-mediated neuroprotective effects. Thus,
guanosine-induced neuroprotection was not affected by the
inhibition of ATP-sensitive K+ channels (with glibenclamide)
or small-conductance Ca2+-activated K+ (SK) channels (with
apamin; Dal-Cim et al., 2011). Indeed, guanosine increased K+
conductance in cells transiently transfected with the functional
α-subunit of BK channels but not with SK channels (Tasca et al.,
2013).
From the reports discussed here, it seems clear that additional
studies are necessary to unravel the putative molecular targets
of guanosine (and even of guanine), in order to understand the
actual complexity of the GBP system.
PERSPECTIVES ON THE GUANINE-BASED
PURINERGIC SYSTEM
GBPs exert a plethora of beneficial (i.e., neuroprotective,
neurotrophic, antidepressant, anxiolytic and analgesic) effects
throughout the CNS. Accordingly, in recent years, much effort
has been devoted to fully characterize these kinds of effects and
elucidating the still unresolved mechanisms of action of these
molecules. Importantly, the lack of identification of putative GBP
receptors, whichmaymediate some of the observed effects (other
receptors, such as glutamate or adenosine receptors, and ion
channels, may also be involved) has slowed this process. For this
reason, in the next few years, an exponential rise in GBP studies
is expected, in which the elucidation of both the mechanism
of action of these molecules and the exact role they play in
some pathologies (e.g., AD and PD) may be the main goals.
Meanwhile, some empirical data can already be successfully used
in a number of clinical situations. For instance, drugs facilitating
the salvage pathway of purine recycling, such as allopurinol,
a xanthine oxidase activity inhibitor, could be included as an
option for refractory epilepsy (Togha et al., 2007). Similarly,
alteration of purine metabolism may be considered a possible
biomarker for PD diagnosis. Thus, a reduction in uric acid
plasma levels can be observed in PD patients (Schwarzschild
et al., 2008), while increased urate levels have been found
in post-mortem PD brains. Altogether, these data reinforce
the notion that purine levels and metabolism may modulate
response of the organism to injury, acting as a retaliatory system
responsible for modulating unbalanced neurotransmission in
damaging situations. Overall, together with evidences showing
that GBPs may have both trophic effects on neural cells and
beneficial behavioral effects, present knowledge of GBP biology
in the CNS supports the rationale for further studies of this
system and the development of novel drugs that may be useful
in the near future.
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